Recent News for SUPN - Supernus Pharmaceuticals, Inc.

Date Title
Apr 13 Supernus approaches LOE for Trokendi, but Jefferies sees ‘a new product cycle’
Apr 13 IRhythm extends losses as more downgrades pile up, Aphria cut to neutral after earnings miss; and more in today’s analyst action
Apr 6 Supernus shares soar 13% after FDA approves its new ADHD drug for children
Apr 5 Why Supernus Pharmaceuticals Stock Is Soaring Today
Apr 5 Supernus (SUPN) Receives FDA Approval for ADHD Treatment
Apr 5 TSLA, NVTA, CHPT and NNOX among premarket gainers
Apr 5 Wall Street Breakfast: Monster Debut
Apr 5 Supernus Higher as Pediatric ADHD Drug Is Cleared by FDA
Apr 5 FDA Approves Supernus’ Qelbree; Shares Rise 10% Pre-Market
Apr 5 FDA OKs Supernus' Qelbree for treatment of ADHD
Apr 4 These 2 Scrappy Biotechs Could Skyrocket in April
Apr 3 The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
Apr 2 Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
Apr 2 Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Mar 24 3 Healthcare Stocks That Could Be Millionaire-Makers
Feb 28 Supernus Pharmaceuticals: Solid Quarter, Solid Stock
Feb 28 Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2020 Results - Earnings Call Transcript
Feb 27 3 Undervalued Biotechs Worth Adding to Your Watch List
Feb 26 Supernus Pharmaceuticals Inc (SUPN) Q4 2020 Earnings Call Transcript
Feb 26 Supernus to Present at Cowen Healthcare Conference
Feb 25 Supernus Pharmaceuticals reports Q4 results
Feb 25 Supernus Pharmaceuticals: Q4 Earnings Insights
Feb 25 Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
Feb 25 Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96
Feb 24 Supernus Pharmaceuticals Q4 2020 Earnings Preview
Back to the Main SUPN Page...